Madrigal Pharmaceuticals Inc (YDO1 F) stock market data APIs
€421.2843
-1.08(-0.3%)
as of January 22, 2026
Try our APIs with
free plan!
Madrigal Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Prev. Close
421.2843
Open
420.2009
High
424.4977
Low
419.1033
52 wk Range
229.5-523.2
Market Cap
9 593 M
Shares Outstanding
22 711 K
Revenue
741 M
EPS
-3.72
Beta
-1.014
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Madrigal Pharmaceuticals Inc data using free add-ons & libraries
Get Madrigal Pharmaceuticals Inc Fundamental Data
Madrigal Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 741 M
- EBITDA: -306 007 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-05
- EPS/Forecast: -3.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Madrigal Pharmaceuticals Inc News
New
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics ...
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics ...
MDGL Secures Exclusive Global Right for MASH Treatment From PFE
Madrigal Pharmaceuticals MDGL has acquired exclusive global rights to ervogastat from Pfizer PFE, strengthening its pipeline of innovative and combination therapies for metabolic dysfunction-associate...
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum
Madrigal Pharmaceuticals (MDGL) is back in focus after recent trading saw the share price move to a last close of US$514.06, with returns mixed over the past week, month and past 3 months. See our la...
Get Madrigal Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
